|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Kanwal F: Epidemiology of
hepatocellular carcinoma in the United States: Where are we? Where
do we go? Hepatology. 60:1767–1775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ren W, Qi X, Jia J, Yang M and Han G:
Hepatocellular carcinoma. Lancet (London, England). 380:469author
reply 470–461. 2012. View Article : Google Scholar
|
|
4
|
Stein MP, Edberg JC, Kimberly RP, Mangan
EK, Bharadwaj D, Mold C and Du Clos TW: C-reactive protein binding
to FcgammaRIIa on human monocytes and neutrophils is
allele-specific. J Clin Invest. 105:369–376. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pepys MB: C-reactive protein: The role of
an ancient protein in modern rheumatology. Clin Exp Rheumatol.
1:3–7. 1983.PubMed/NCBI
|
|
6
|
Hefler LA, Concin N, Hofstetter G, Marth
C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C,
et al: Serum C-reactive protein as independent prognostic variable
in patients with ovarian cancer. Clin Cancer Res. 14:710–714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu M, Zhu M, Du Y, Yan B, Wang Q, Wang C
and Zhao J: Serum C-reactive protein and risk of lung cancer: A
case-control study. Med Oncol. 30:3192013. View Article : Google Scholar
|
|
8
|
Chung YC and Chang YF: Serum C-reactive
protein correlates with survival in colorectal cancer patients but
is not an independent prognostic indicator. Eur J Gastroenterol
Hepatol. 15:369–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bataille R, Boccadoro M, Klein B, Durie B
and Pileri A: C-reactive protein and beta-2 microglobulin produce a
simple and powerful myeloma staging system. Blood. 80:733–737.
1992.PubMed/NCBI
|
|
10
|
Legouffe E, Rodriguez C, Picot MC, Richard
B, Klein B, Rossi JF and Commes T: C-reactive protein serum level
is a valuable and simple prognostic marker in non Hodgkin's
lymphoma. Leuk Lymphoma. 31:351–357. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang J, Wezeman M, Zhang X, Lin P, Wang M,
Qian J, Wan B, Kwak LW, Yu L and Yi Q: Human C-reactive protein
binds activating Fcgamma receptors and protects myeloma tumor cells
from apoptosis. Cancer Cell. 12:252–265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu F, Chen HY, Huang XR, Chung AC, Zhou
L, Fu P, Szalai AJ and Lan HY: C-reactive protein promotes diabetic
kidney disease in a mouse model of type 1 diabetes. Diabetologia.
54:2713–2723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ho J, Kong JW, Choong LY, Loh MC, Toy W,
Chong PK, Wong CH, Wong CY, Shah N and Lim YP: Novel breast cancer
metastasis-associated proteins. J Proteome Res. 8:583–594. 2009.
View Article : Google Scholar
|
|
14
|
Hu H, Ding X, Yang Y, Zhang H, Li H, Tong
S, An X, Zhong Q, Liu X, Ma L, et al: Changes in
glucose-6-phosphate dehydrogenase expression results in altered
behavior of HBV-associated liver cancer cells. Am J Physiol
Gastrointest Liver Physiol. 307:G611–G622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ran X, Xu X, Yang Y, She S, Yang M, Li S,
Peng H, Ding X, Hu H, Hu P, et al: A quantitative proteomics study
on olfactomedin 4 in the development of gastric cancer. Int J
Oncol. 47:1932–1944. 2015.PubMed/NCBI
|
|
16
|
Wang LN, Tong SW, Hu HD, Ye F, Li SL, Ren
H, Zhang DZ, Xiang R and Yang YX: Quantitative proteome analysis of
ovarian cancer tissues using a iTRAQ approach. J Cell Biochem.
113:3762–3772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Y, Toy W, Choong LY, Hou P, Ashktorab
H, Smoot DT, Yeoh KG and Lim YP: Discovery of SLC3A2 cell membrane
protein as a potential gastric cancer biomarker: Implications in
molecular imaging. J Proteome Res. 11:5736–5747. 2012.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Gan CS, Chong PK, Pham TK and Wright PC:
Technical, experimental, and biological variations in isobaric tags
for relative and absolute quantitation (iTRAQ). J Proteome Res.
6:821–827. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou C, Simpson KL, Lancashire LJ, Walker
MJ, Dawson MJ, Unwin RD, Rembielak A, Price P, West C, Dive C, et
al: Statistical considerations of optimal study design for human
plasma proteomics and biomarker discovery. J Proteome Res.
11:2103–2113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krishnamachary B, Berg-Dixon S, Kelly B,
Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi
P, et al: Regulation of colon carcinoma cell invasion by
hypoxia-inducible factor 1. Cancer Res. 63:1138–1143.
2003.PubMed/NCBI
|
|
22
|
Dian D, Heublein S, Wiest I, Barthell L,
Friese K and Jeschke U: Significance of the tumor protease
cathepsin D for the biology of breast cancer. Histol Histopathol.
29:433–438. 2014.
|
|
23
|
Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK,
Kim HK, Kim JS and Oh SC: Sonic hedgehog pathway promotes
metastasis and lymphangiogenesis via activation of Akt, EMT, and
MMP-9 pathway in gastric cancer. Cancer Res. 71:7061–7070. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Gu Z, Wu M, Yang Y, Zhang J, Ou J,
Zuo Z, Wang J and Chen Y: C-reactive protein can upregulate VEGF
expression to promote ADSC-induced angiogenesis by activating
HIF-1α via CD64/PI3k/Akt and MAPK/ERK signaling pathways. Stem Cell
Res Ther. 7:1142016. View Article : Google Scholar
|
|
25
|
Lee IN, Chen CH, Sheu JC, Lee HS, Huang
GT, Chen DS, Yu CY, Wen CL, Lu FJ and Chow LP: Identification of
complement C3a as a candidate biomarker in human chronic hepatitis
C and HCV-related hepatocellular carcinoma using a proteomics
approach. Proteomics. 6:2865–2873. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng JT, Liu YK, Song HY, Dai Z, Qin LX,
Almofti MR, Fang CY, Lu HJ, Yang PY and Tang ZY: Heat-shock protein
27: A potential biomarker for hepatocellular carcinoma identified
by serum proteome analysis. Proteomics. 5:4581–4588. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
She S, Xiang Y, Yang M, Ding X, Liu X, Ma
L, Liu Q, Liu B, Lu Z, Li S, et al: C-reactive protein is a
biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int
J Oncol. 47:543–554. 2015.PubMed/NCBI
|
|
28
|
Westley B and Rochefort H: A secreted
glycoprotein induced by estrogen in human breast cancer cell lines.
Cell. 20:353–362. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rochefort H, Capony F, Garcia M, Cavaillès
V, Freiss G, Chambon M, Morisset M and Vignon F: Estrogen-induced
lysosomal proteases secreted by breast cancer cells: A role in
carcinogenesis? J Cell Biochem. 35:17–29. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berchem G, Glondu M, Gleizes M, Brouillet
JP, Vignon F, Garcia M and Liaudet-Coopman E: Cathepsin-D affects
multiple tumor progression steps in vivo: Proliferation,
angiogenesis and apoptosis. Oncogene. 21:5951–5955. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vashishta A, Ohri SS, Proctor M, Fusek M
and Vetvicka V: Ribozyme-targeting procathepsin D and its effect on
invasion and growth of breast cancer cells: An implication in
breast cancer therapy. Int J Oncol. 30:1223–1230. 2007.PubMed/NCBI
|
|
32
|
Glondu M, Liaudet-Coopman E, Derocq D,
Platet N, Rochefort H and Garcia M: Down-regulation of cathepsin-D
expression by antisense gene transfer inhibits tumor growth and
experimental lung metastasis of human breast cancer cells.
Oncogene. 21:5127–5134. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Briozzo P, Badet J, Capony F, Pieri I,
Montcourrier P, Barritault D and Rochefort H: MCF7 mammary cancer
cells respond to bFGF and internalize it following its release from
extracellular matrix: A permissive role of cathepsin D. Exp Cell
Res. 194:252–259. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Piwnica D, Fernandez I, Binart N, Touraine
P, Kelly PA and Goffin V: A new mechanism for prolactin processing
into 16K PRL by secreted cathepsin D. Mol Endocrinol. 20:3263–3278.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011.PubMed/NCBI
|
|
36
|
Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS
and Wu KJ: Prognostic significance of hypoxia-inducible
factor-1alpha, TWIST1 and Snail expression in resectable non-small
cell lung cancer. Thorax. 64:1082–1089. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim SJ, Rabbani ZN, Dewhirst MW,
Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E and Kelley MJ:
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically
resected non-small cell lung cancer. Lung Cancer. 49:325–335. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation
of hypoxia inducible factor 1 alpha and 2 alpha in operable
non-small cell lung cancer to angiogenic/molecular profile of
tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
